Alembic Pharmaceuticals Ltd Share Price Today - Alembic Pharmaceuticals Ltd Stock Price Live NSE/BSE

Alembic Pharmaceuticals Ltd

NSE: APLLTD BSE: 533573

₹793.80

(0.86%)

Sun, 17 May 2026, 07:19 am

MTF 5xInvest in Alembic Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap154.38B

PE Ratio24.81

Dividend1.40

Health Technology

Pharmaceuticals: Major

24.5K

Alembic Pharmaceuticals Share Price Live Chart

1 Day

(0.86%)

No Result Found

Summary

Market Cap
15424.31
Net Profit
582.01
P/B
3.52
Sector P/E
35.36
P/E
31.31
EV/EBITDA
18.25
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
11.63
ROCE
13.08
Debt/Equity
0.18
EPS (TTM)
37.11
Dividend Yield
1.53
Book Value
288.70
Interest Cover
9.98

Analysis

all

Pros

Dividends paid are well covered by earnings (6.3x coverage).
Dividends after 3 years are expected to be well covered by earnings (4.4x coverage).
Alembic Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Cash flow for Alembic Pharmaceuticals is expected to increase by more than 50% in 2 years time.
Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.

Cons

Dividend payments have increased, but Alembic Pharmaceuticals only paid a dividend in the past 8 years.
Whilst dividend payments have been stable, Alembic Pharmaceuticals has been paying a dividend for less than 10 years.
Alembic Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
Alembic Pharmaceuticals's earnings are expected to grow by 0.5% yearly, however this is not considered high growth (20% yearly).
Alembic Pharmaceuticals's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	69.74	69.74	69.74	69.67	69.67
FII	4.25	4.24	4.05	3.96	3.94
DII	16.18	16.17	16.30	16.46	16.43
Public	9.83	9.85	9.92	9.90	9.96
Government	0	0	0	0	0

Technical Analysis

RSI

59.40

MACD

14.91

50 DMA

724.04

200 DMA

847.26

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1037.17	884.67	819.83	732.17	667.33	579.67	427.17
Fibonacci	884.67	826.41	790.42	732.17	673.91	637.92	579.67
Camarilla	796.94	782.96	768.98	732.17	741.02	727.04	713.06

Pivots Level: Classic

+305.00

1037.17

+152.50

884.67

+87.67

819.83

732.17

Pivot Point

LTP: 784.10

-64.83

667.33

-152.50

579.67

-305

427.17

Moving Average

SMAEMA

Period

Value

10-EMA
775.95
20-EMA
764.80
30-EMA
756.07
50-EMA
751.71
100-EMA
772.97
200-EMA
822.08

Announcement Date	Purpose	Action	Ex Date
15 May 2026	board-meetings	Accounts, Dividend
05 Feb 2026	board-meetings	Quarterly Results, Nine Months Results
04 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
29 Jun 2025	dividend	Final Dividend - Rs. - 11	29 Jul 2025
11 Jun 2025	agm
06 May 2025	dividend	₹11.00 Dividend /Share	29 Jul 2025
21 Jun 2024	agm
15 Jun 2024	dividend	Final Dividend - Rs. - 11	15 Jul 2024
09 May 2024	dividend	₹11.00 Dividend /Share	15 Jul 2024
28 Jun 2023	dividend	Final Dividend - Rs. - 8	28 Jul 2023

Alembic Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Divis Laboratories Ltd

Alembic Pharmaceuticals Ltd About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2010

Headquarters

CEO

Chirayu R Amin

Employees

Contact

Website

http://www.alembicpharmaceuticals.com/

apl.investors@alembic.co.in

Phone

91-0265-2280550

Location

Alembic Road, , Vadodara, Gujarat, 390003

Year	History
2021	Alembic receives USFDA tentative approval for Selexipag Tablets. Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules. Alembic Pharma gets USFDA nod for cancer treatment drug. Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP.
2022	Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules. Alembic Pharma gets USFDA nod for Entacapone tablets. Alembic Pharmaceuticals gets US FDA nod for antibiotic drug.
2023	Alembic has a cumulative total of 182 ANDA approvals from USFDA.
2024	Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy. Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia. Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg
2025	Alembic Pharmaceuticals Ltd. announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Alembic Pharmaceuticals Ltd has received final approval from the USFDA for its generic version of Sumatriptan Injection. Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Carbamazepine extended-release tablets. Alembic Pharmaceuticals Ltd. has received USFDA Final Approval for Ticagrelor Tablets, 60 mg. Alembic Pharmaceuticals Ltd. announces USFDA Final Approval for Bosutinib Tablets, 100 mg and 500 mg.

Client Name	Deal Type	Order Side	QTY	Avg Price	Date
ISHARES INDIA SC MAURITIUS COMPANY	block	Sell	25903	611.25	11 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETF	block	Buy	184251	611.25	11 Oct 2022
ISHARES MSCI INDIA SMALL-CAP ETF	block	Buy	25903	611.25	11 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS CO	block	Sell	184251	611.25	11 Oct 2022
ISHARES INDIA SC MAURITIUS COMPANY	block	Sell	25151	604.65	03 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS CO	block	Sell	178908	604.65	03 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETF	block	Buy	178908	604.65	03 Oct 2022
ISHARES MSCI INDIA SMALL-CAP ETF	block	Buy	25151	604.65	03 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETF	block	Buy	194642	609.9	19 Sept 2022
ISHARES CORE EMERGING MARKETS MAURITIUS CO	block	Sell	194642	609.9	19 Sept 2022

Alembic Pharmaceuticals Ltd News

Alembic Pharma Clears Anvisa GMP Inspection at Karakhadi API-III

Alembic Pharmaceuticals successfully passes Brazil's Anvisa GMP inspection at its Karakhadi API-III facility, completing inspection for multiple APIs without any issues.

15 May 2026

companies

Alembic Pharma Q4 Profit Rises, Margins Compress

Alembic Pharma Q4 net profit rose to 2B rupees from 1.6B YoY, while revenue grew to 18.5B rupees. EBITDA margin contracted to 12.34% from 15.4% YoY.

15 May 2026

companies

Alembic Pharma SVP Strategy Resigns Effective May 14

Rohit Garg, Senior Vice President – Strategy & Business Excellence at Alembic Pharmaceuticals, resigned citing personal reasons, with relief effective 14th May, 2026.

15 May 2026

companies

Alembic Pharma Gets USFDA Tentative Nod for Darolutamide Tablets

Alembic Pharmaceuticals receives tentative USFDA approval for 300 MG Darolutamide Tablets, a generic equivalent to Nubeqa Tablets, in a US market estimated at $3.155 billion.

14 May 2026

companies

Alembic Pharma Notifies Shareholders on IEPF Share Transfer

Alembic Pharmaceuticals notifies shareholders of IEPF share transfer for unclaimed dividends from FY2018-19 onwards. Shareholders must claim by 10/08/2026 or shares will be transferred.

05 May 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800